Microsoft has quietly added another entry to its ever-growing list of deprecated Windows features. The company is phasing out ...

Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming ...

Internal investigations often start small. A complaint, a suspicious transaction, or a red flag in a routine audit. Most ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...